Renalytix Plc
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.- Similar Companies
- Business
- Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
Company News
Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US
Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination
Medicare Issues Final Coverage Determination for kidneyintelX.dkd
Renalytix Plc (RNLX) Q3 2024 Earnings Call Transcript
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024
Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15
Renalytix Announces Financing with Expected Size of up to $4 Million
3 Ridiculously Enticing Stocks to Buy for Under a Buck
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
Renalytix slides by a third as funding moves front and centre
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Renalytix rises on draft Medicare determination
New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease
Renalytix Plc (RNLX) Q1 2024 Earnings Call Transcript
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024
Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14
New Strong Buy Stocks for October 26th
What Makes Renalytix AI PLC Sponsored ADR (RNLX) a New Strong Buy Stock
New Strong Buy Stocks for October 12th